Filing Flows › Comparisons › EXEL vs HALO
Exelixis vs Halozyme Therapeutics: EXEL and HALO compared
Exelixis is the larger company: $659M of revenue in its latest quarter (Q3 2026) against $493M for Halozyme Therapeutics (Q3 2026). Halozyme Therapeutics is growing faster (+39% against +10% a year earlier). Halozyme Therapeutics is more profitable, with an operating margin of 59.8% against 40.8%.
Where the money goes: EXEL and HALO
Exelixis (EXEL) · Q3 2026
Exelixis, Q3 2026: revenue $659M (+10% year over year), operating margin 40.8%, net earnings $218M, operating cash flow $280M. The chart follows the revenue to costs, profit and cash.
Halozyme Therapeutics (HALO) · Q3 2026
Halozyme Therapeutics, Q3 2026: revenue $493M (+39% year over year), operating margin 59.8%, net earnings $247M, operating cash flow $258M. The chart follows the revenue to costs, profit and cash.
| Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $659M | $493M |
| Revenue growth, Y/Y | +10% | +39% |
| Operating margin | 40.8% | 59.8% |
| Net earnings | $218M | $247M |
| Net margin | 33.1% | 50.1% |
| Operating cash flow | $280M | $258M |
| Free cash flow | $277M | $255M |
| Market value | $17.8B | $12.7B |
| P/E | 20.8× | 26.2× |
| Analysts’ mean target | $61.57 | $109.67 |
Where the revenue comes from
Exelixis
- Net product revenues: $605M (92%)
- Collaboration: $53.8M (8%)
- COMETRIQ: $1.8M (0%)
Halozyme Therapeutics
- Royalties: $341M (69%)
- Product sales, net: $137M (28%)
- Revenues under collaborative agreements: $14.6M (3%)
Questions
Which is bigger, Exelixis or Halozyme Therapeutics?
Exelixis is the larger company: $659M of revenue in its latest quarter (Q3 2026) against $493M for Halozyme Therapeutics (Q3 2026).
Is Exelixis or Halozyme Therapeutics growing faster?
Halozyme Therapeutics is growing faster (+39% against +10% a year earlier).
Which is more profitable, Exelixis or Halozyme Therapeutics?
Halozyme Therapeutics is more profitable, with an operating margin of 59.8% against 40.8%.
More: Exelixis earnings · how Exelixis makes money · Halozyme Therapeutics earnings · how Halozyme Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 29, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.